Table 2.
Summary of Response Rates Before and After Propensity Score Matching
| Best Overall Response, n (%) | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| R+ICIs (N=24) | R+ICIs+TACE (N=28) | P value | R+ICIs (N=23) | R+ICIs+TACE (N=23) | P value | |
| CR | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) | – |
| PR | 1 (4.2) | 10 (35.7) | 0.005 | 1 (4.3) | 8 (34.8) | 0.009 |
| SD | 9 (37.5) | 9 (32.1) | 0.686 | 9 (39.1) | 8 (34.8) | 0.760 |
| PD | 14 (58.3) | 9 (32.1) | 0.058 | 13 (56.5) | 7 (30.4) | 0.074 |
| ORR | 1 (4.2) | 10 (35.7) | 0.005 | 1 (4.3) | 8 (34.8) | 0.009 |
| DCR | 10 (41.7) | 19 (67.9) | 0.058 | 10 (43.5) | 16 (69.6) | 0.074 |
Abbreviations: PSM, propensity score matching; R+ICIs, regorafenib+immune checkpoint inhibitor; R+ICIs+TACE, regorafenib+immune checkpoint inhibitors+transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.